Ceritinib in ALK-rearranged non-small-cell lung cancer

New England Journal of Medicine

Volumn 370, Issue 13, 2014, Pages 1189-1197

  Shaw, Alice T ^a   Kim, Dong Wan ^b   Mehra, Ranee ^c   Tan, Daniel S W ^d   Felip, Enriqueta ^e   Chow, Laura Q M ^f   Camidge, D Ross ^g   Vansteenkiste, Johan ^h   Sharma, Sunil ⁱ   De Pas, Tommaso ^j   Riely, Gregory J ^l   Solomon, Benjamin J ^m   Wolf, Juergen ⁿ   Thomas, Michael ^o   Schuler, Martin ^p,q   Liu, Geoffrey ^r   Santoro, Armando ^k   Lau, Yvonne Y ^s   Goldwasser, Meredith ^s   Boral, Anthony L ^s   Engelman, Jeffrey A ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Seoul National University Hospital   (South Korea)

^c FOX CHASE CANCER CENTER   (United States)

^d GENOME INSTITUTE OF SINGAPORE   (Singapore)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ UNIVERSITY OF UTAH   (United States)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m PETER MACCALLUM CANCER CENTRE   (Australia)

ⁿ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^o UNIVERSITY OF HEIDELBERG   (Germany)

^p GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^q UNIVERSITY OF DUISBURG ESSEN   (Germany)

^r PRINCESS MARGARET HOSPITAL   (Canada)

^s NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ANAPLASTIC LYMPHOMA KINASE; ASPARTATE AMINOTRANSFERASE; CERITINIB; CRIZOTINIB; TRIACYLGLYCEROL LIPASE;

ADULT; ADVANCED CANCER; AGED; ALK GENE; ARTICLE; BLOOD LEVEL; CANCER FATIGUE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; LUNG BIOPSY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; NAUSEA; ONCOGENE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; SURVIVAL RATE; SURVIVAL TIME; TUMOR BIOPSY; VERY ELDERLY; VOMITING; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECOMBINATION, GENETIC; SULFONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896957081     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1311107     Document Type: Article

References (28)

1. Barreca A, Lasorsa E, Riera L, et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol 2011;47:R11-R23.
2. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-83.
3. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-7.
4. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-33.
5. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional upregulation in non-small cell lung carcinomas. Hum Pathol 2009;40:1152-8.
6. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009;174:661-70.
7. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-23. [Erratum, Clin Cancer Res 2009;15:7110.]
8. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010;17:889-97.
9. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-9.
10. Kim DW, Ahn MJ, Shi Y, et al. Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer. Presented at the European Society for Medical Oncology Annual Congress, Vienna, September 28-October 2, 2012. abstract.
11. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
12. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012;4:120ra17.
13. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82.
14. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10:281-9.
15. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2(3):e73.
16. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92. (Pubitemid 40271173)
17. Roumiantsev S, Shah NP, Gorre ME, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A 2002;99:10700-5.
18. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80. (Pubitemid 32743979)
19. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol 2013;31:1105-11.
20. National Comprehensive Cancer Network. NCCN guidelines: non-small-cell lung cancer, v2. 2013 (http://www.nccn.org/professionals/physician-gls/recently- updated.asp).
21. Marsilje TH, Pei W, Chen B, et al. Synthesis, structure-activity relationships and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor LDK378 currently in phase 1 and 2 clinical trials. J Med Chem 2013;56:5675-90.
22. Li N, Michellys PY, Kim S, et al. Activity of a potent and selective phase I ALK inhibitor LDK378 in naive and crizotinib-resistant preclinical tumor models. Presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, November 12-16, 2011. abstract.
23. Shaw AT, Mehra R, Kim D-W, et al. Clinical activity of the ALK Inhibitor LDK378 in advanced, ALK-positive NSCL. Presented at the Annual Meeting of the American Society of Clinical Oncology, Chicago, May 31-June 4, 2013. abstract.
24. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 1998;17:1103-20. (Pubitemid 28221028)
25. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 2008;27:2420-39. (Pubitemid 351802902)
26. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13:528-38. [Erratum, Lancet Oncol 2012;13(5):e186.]
27. Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:3076-83.
28. Campbell A, Reckamp KL, Camidge DR, et al. PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): a phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). Presented at the Annual Meeting of the American Society of Clinical Oncology, Chicago, June 4-8, 2010. abstract.